Sound View Wealth Advisors Group LLC Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sound View Wealth Advisors Group LLC increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,315 shares of the specialty pharmaceutical company’s stock after buying an additional 206 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Jazz Pharmaceuticals were worth $1,024,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. Ruffer LLP purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $7,237,000. PNC Financial Services Group Inc. increased its position in Jazz Pharmaceuticals by 8.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,749 shares of the specialty pharmaceutical company’s stock worth $585,000 after purchasing an additional 374 shares during the last quarter. Callan Family Office LLC purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $267,000. Lindbrook Capital LLC lifted its position in Jazz Pharmaceuticals by 82.6% during the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 176 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth $11,373,000. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $138.81 on Monday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $8.43 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The firm has a 50-day moving average of $128.14 and a two-hundred day moving average of $120.07. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06.

Insider Activity

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,193 shares of company stock valued at $3,533,122. Corporate insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Barclays reaffirmed an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $145.00 to $179.00 in a research report on Friday. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Finally, Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and an average target price of $189.40.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.